Skip to main content
. 2021 Mar 15;12:627535. doi: 10.3389/fimmu.2021.627535

Figure 2.

Figure 2

TREM-1 signaling does not affect anti-TNF induced differentiation of regulatory type macrophages. (A) Percentage of CD206+CD14+ cells in a mixed lymphocyte reaction with anti-TNF (adalumimab, 10 µg/ml), IgG isotype control (10 µg/ml) in combination with the agonistic TREM-1 antibody or relevant isotype control (both 10 µg/ml). (B) TREM-1 MFI of the CD14+CD206+ population in the MLR. (D) Percentage of CD206+CD14+ cells in a mixed lymphocyte reaction with anti-TNF, IgG isotype control in combination with the TREM inhibitor LR12 (50 µg/ml), and 6-TG (25 µM) or DMSO control. TNFα production by monocytes stimulated for 24 hours with the agonistic TREM-1 antibody (10 µg/ml) in (C) and with LPS (100 ng/ml) in combination with LR12 (50 µg/ml) in (E). Representative (n=3-5 per condition) of 3 to 4 different independent experiments using different donors. Significance was determined by ANOVA followed by Sidak’s multiple comparison test in A/B/D and unpaired t-test in C/E with *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.